Previous studies demonstrated that AKT plays a central role in mediating the antiprostate cancer effect of EF, and PI3K was predicted to be the potential target of evodiamine to inhibit proliferation and migration of prostate cancer. This evidence concerns the gene AKT1 and cancer.